

The Effect of Continuous Diffusion of Oxygen Adjunct Therapy for Surgically Closed Wounds in Ischemic Diabetic Foot Patients – A Pilot Randomized Controlled Trial Study

Pedram Bayat, Alejandro Zulbaran, MD, Catherine Park, PhD, Rasha Bara, BS Areli Flores, MD, Jeffrey A. Ross, DPM, MD, Brian Lepow, DPM, Bijan Najafi, PhD

2022 Los Angeles, CA

Division of Vascular Surgery and Endovascular Therapy, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, USA

OBJECTIVE

ASSESS THE USEFULNESS OF CONTINUOUS DIFFUSION OF OXYGEN TO BOOST HEALING PROCESS OF SURGICALLY CLOSED WOUNDS

INTRODUCTION

- ❖ Significance & Impact: Ischemic diabetic foot (IDF) encompasses a 31% conversion rate to minor amputations¹. If mistreated, this procedure may lead to tissue necrosis, infection, or dehiscence^{2,3}.
- ❖ Premise: Topical oxygen therapy is effective in treating non-healing open wounds⁴. When applied in a constant delivery fashion through continuous diffusion of oxygen (CDO), it has shown to increase wound healing compared to standard wound therapy^{5,6}.
- ❖ Gaps: Our preliminary study showed moderate CDO flow (8 ml/hr) reduced wound length in IDF
 ↑ Patients undergoing minor constability patients undergoing minor amputations; however adverse events accompanied⁷.
- Solution: We propose to examine effectiveness of CDO (OxyGeni®, EO2 Concepts, TX, Fig. 1) at a lower flow (4 ml/hr) to the standard of care (SOC) dressing.
- Hypothesis: CDO will accelerate the healing of surgically closed ischemic wounds and reduce hospital readmissions in diabetic patients undergoing minor amputations.



Figure 1: OxyGeni® Portable CDO System with a directed cannula to the SOC dressing (EO₂ Concepts, San Antonio, TX)

MATERIALS & METHODS

- ❖ Study design: Randomized control trial (N=15) of patients undergoing minor amputations
- (n=14 hallux, n=1 transmetatarsal)
- Control Group (n = 11): SOC
- Intervention Group (n = 4): SOC + CDO (4 ml/hr)
- Duration: 4 weeks

- Inclusion: 18-85 years, diabetes mellitus type 2, presence of a surgically closed wound due to minor lower extremity amputation.
- Exclusion: Charcot arthroplasty, osteomyelitis, or excessive lymphedema

Outcomes


- 30-day incidence of wound complications:
 - Necrosis, dehiscence, infection
- 30-day hospital readmissions

Indications for procedures:

- Gangrene (n=11)
- Infection (n=2)
- Non-healing ulceration (n=2)

Demographics	Mean SD/ no. (%)	P value
Age, years	64.3±9.4	0.81
BMI, kg/m2	28.2±6.5	0.98
HbA1c, mmol	7.8±1.9	0.08
Previous 30-day revascularization	53.3%	0.87
Heart disease	46.7%	0.31
Chronic kidney disease	40.0%	0.09

RESULTS & FINDINGS



30-day wound complications p=0.31*OR=3.67 60 *g=0.3**%** 40 54.5% 20 25% SOC **CDO** 30-day hospital readmissions p=0.24*g=0.24% 20 27.3% 0%

DISCUSSION & CONCLUSION

- ❖ This is the first study reporting potential effectiveness of CDO in improving surgically closed wound outcomes for IDF patients.
- * A positive non-significant trend in favor of CDO may indicate potential benefit to reduce adverse outcomes and hospital readmission in diabetic patients undergoing minor amputations.
- ❖ A higher sample size is warranted to confirm this statement.

CDO REFERENCES

- 1. P Sen, et al. Diabetes Metab Res Rev. 2019 Oct;35(7):e3165.
- 2. Sen K, et al. Wound Repair Regan. 2009; 17(1): 1-18.
- 3. Wernick B, et al. StatPearls Publishing; 2020. 4. Dissemond, et al. MAG Online Library; 2015.
- 5. Niederauer M, et al. Journal of Wound Care; 2018.

SOC

- 6. Niederauer M, et al. Journal of Diabetes Science and Technology; 2017
- 7. Zulbaran A. SAWC Network. 2020; https://www.hmpgloballearningnetwork.com

ACKNOWLEDGEMENT

- This study was supported in part by a grant from EO2 Concepts Inc. Sponsors did not contribute in participant recruitment nor in data analysis or interpretation of results.
- The study was registered in ClinicalTrials.gov identifier: NCT03960463.

